Y Intercept Hong Kong Ltd Invests $1.83 Million in Day One Biopharmaceuticals, Inc. $DAWN

Y Intercept Hong Kong Ltd purchased a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 281,528 shares of the company’s stock, valued at approximately $1,830,000. Y Intercept Hong Kong Ltd owned approximately 0.28% of Day One Biopharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Day One Biopharmaceuticals during the 2nd quarter worth approximately $76,000. GC Wealth Management RIA LLC purchased a new position in shares of Day One Biopharmaceuticals during the second quarter valued at $520,000. Rhumbline Advisers raised its position in Day One Biopharmaceuticals by 8.3% during the first quarter. Rhumbline Advisers now owns 81,844 shares of the company’s stock valued at $649,000 after buying an additional 6,291 shares during the period. Jane Street Group LLC purchased a new stake in Day One Biopharmaceuticals in the 1st quarter worth about $245,000. Finally, Optimize Financial Inc boosted its position in Day One Biopharmaceuticals by 16.0% during the 1st quarter. Optimize Financial Inc now owns 17,960 shares of the company’s stock worth $142,000 after acquiring an additional 2,473 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Up 5.7%

Day One Biopharmaceuticals stock opened at $7.44 on Friday. The company has a market capitalization of $762.08 million, a P/E ratio of -7.83 and a beta of -1.26. The firm’s fifty day simple moving average is $7.27 and its 200-day simple moving average is $6.92. Day One Biopharmaceuticals, Inc. has a 1-year low of $5.64 and a 1-year high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $33.91 million during the quarter, compared to analysts’ expectations of $35.55 million. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative return on equity of 19.01%. On average, equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,365 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.77, for a total transaction of $29,551.05. Following the completion of the sale, the insider owned 54,858 shares of the company’s stock, valued at $371,388.66. This represents a 7.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles N. York II sold 4,106 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $6.77, for a total value of $27,797.62. Following the transaction, the chief financial officer owned 278,000 shares in the company, valued at approximately $1,882,060. This trade represents a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 28,295 shares of company stock worth $191,557. Insiders own 6.20% of the company’s stock.

Analyst Ratings Changes

DAWN has been the topic of a number of research reports. HC Wainwright dropped their target price on Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Thursday. Needham & Company LLC decreased their target price on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Piper Sandler started coverage on shares of Day One Biopharmaceuticals in a report on Monday, August 18th. They set an “overweight” rating and a $25.00 price target on the stock. Finally, Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.29.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.